Biomea Fusion announces presentation of two posters for BMF-650, icovamenib

Biomea Fusion (BMEA) announced the presentation of two late breaking posters at ObesityWeek 2025 in Atlanta, Georgia. The presentations highlighted preclinical data for BMF-650, Biomea’s investigational next-generation oral small molecule GLP-1 RA, and combination data for icovamenib, the Company’s potential best-in-class covalent menin inhibitor product candidate, with semaglutide, an injectable GLP-1 based therapy. Key highlights: The Company’s investigational small molecule glucagon-like peptide-1 receptor agonist, BMF-650, demonstrated potent weight loss and good tolerability in obese cynomolgus monkeys; A Phase I study of BMF-650 in healthy obese patients is currently enrolling with data expected first half of 2026; In a rodent model of type 2 diabetes, icovamenib in combination with low dose semaglutide promoted enhanced glycemic control and body weight reduction with preservation of lean mass, outperforming the group given low dose semaglutide alone